Therapeutic | Ganitumab |
Target | IGF1R |
Heavy Chain | QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS |
Light Chain | DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | Amgen%3BMillennium%3BNantWorks%3BNational Cancer Institute %28USA%29%3BNovartis%3BTakeda%3BTakeda Oncology%3BUCLAs Jonsson Comprehensive Cancer Center |
Conditions Approved | na |
Conditions Active | Ewing%27s sarcoma%3BSolid tumours%3BRhabdomyosarcoma |
Conditions Discontinued | Breast cancer%3BColorectal cancer%3BSarcoma%3BSmall cell lung cancer%3BNon-small cell lung cancer%3BPancreatic cancer%3BProstate cancer |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]